289 related articles for article (PubMed ID: 15709009)
1. Cellular and humoral immunity following Snow Mountain virus challenge.
Lindesmith L; Moe C; Lependu J; Frelinger JA; Treanor J; Baric RS
J Virol; 2005 Mar; 79(5):2900-9. PubMed ID: 15709009
[TBL] [Abstract][Full Text] [Related]
2. Heterotypic humoral and cellular immune responses following Norwalk virus infection.
Lindesmith LC; Donaldson E; Leon J; Moe CL; Frelinger JA; Johnston RE; Weber DJ; Baric RS
J Virol; 2010 Feb; 84(4):1800-15. PubMed ID: 20007270
[TBL] [Abstract][Full Text] [Related]
3. Mucosal and Cellular Immune Responses to Norwalk Virus.
Ramani S; Neill FH; Opekun AR; Gilger MA; Graham DY; Estes MK; Atmar RL
J Infect Dis; 2015 Aug; 212(3):397-405. PubMed ID: 25635121
[TBL] [Abstract][Full Text] [Related]
4. Cytokine and antibody responses in gnotobiotic pigs after infection with human norovirus genogroup II.4 (HS66 strain).
Souza M; Cheetham SM; Azevedo MS; Costantini V; Saif LJ
J Virol; 2007 Sep; 81(17):9183-92. PubMed ID: 17581999
[TBL] [Abstract][Full Text] [Related]
5. Application of salivary antibody immunoassays for the detection of incident infections with Norwalk virus in a group of volunteers.
Griffin SM; Converse RR; Leon JS; Wade TJ; Jiang X; Moe CL; Egorov AI
J Immunol Methods; 2015 Sep; 424():53-63. PubMed ID: 25985985
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis and immune responses in gnotobiotic calves after infection with the genogroup II.4-HS66 strain of human norovirus.
Souza M; Azevedo MS; Jung K; Cheetham S; Saif LJ
J Virol; 2008 Feb; 82(4):1777-86. PubMed ID: 18045944
[TBL] [Abstract][Full Text] [Related]
7. Intranasal administration of a recombinant adenovirus expressing the norovirus capsid protein stimulates specific humoral, mucosal, and cellular immune responses in mice.
Guo L; Wang J; Zhou H; Si H; Wang M; Song J; Han B; Shu Y; Ren L; Qu J; Hung T
Vaccine; 2008 Jan; 26(4):460-8. PubMed ID: 18160189
[TBL] [Abstract][Full Text] [Related]
8. Virus-Host Interactions Between Nonsecretors and Human Norovirus.
Lindesmith LC; Brewer-Jensen PD; Mallory ML; Jensen K; Yount BL; Costantini V; Collins MH; Edwards CE; Sheahan TP; Vinjé J; Baric RS
Cell Mol Gastroenterol Hepatol; 2020; 10(2):245-267. PubMed ID: 32289501
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis of norwalk virus infection by indirect enzyme immunoassay detection of salivary antibodies to recombinant norwalk virus antigen.
Moe CL; Sair A; Lindesmith L; Estes MK; Jaykus LA
Clin Diagn Lab Immunol; 2004 Nov; 11(6):1028-34. PubMed ID: 15539501
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of antibodies to the Hawaii strain of human calicivirus as measured by a recombinant protein based immunoassay.
Cubitt WD; Green KY; Payment P
J Med Virol; 1998 Feb; 54(2):135-9. PubMed ID: 9496372
[TBL] [Abstract][Full Text] [Related]
11. Human norovirus infection and the acute serum cytokine response.
Newman KL; Moe CL; Kirby AE; Flanders WD; Parkos CA; Leon JS
Clin Exp Immunol; 2015 Nov; 182(2):195-203. PubMed ID: 26178578
[TBL] [Abstract][Full Text] [Related]
12. Dose-Response of a Norovirus GII.2 Controlled Human Challenge Model Inoculum.
Rouphael N; Beck A; Kirby AE; Liu P; Natrajan MS; Lai L; Phadke V; Winston J; Raabe V; Collins MH; Girmay T; Alvarez A; Beydoun N; Karmali V; Altieri-Rivera J; Lindesmith LC; Anderson EJ; Wang Y; El-Khorazaty J; Petrie C; Baric RS; Baqar S; Moe CL; Mulligan MJ
J Infect Dis; 2022 Nov; 226(10):1771-1780. PubMed ID: 35137154
[TBL] [Abstract][Full Text] [Related]
13. Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes.
Malm M; Tamminen K; Heinimäki S; Vesikari T; Blazevic V
Vaccine; 2018 Jan; 36(4):484-490. PubMed ID: 29246474
[TBL] [Abstract][Full Text] [Related]
14. Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice.
Harrington PR; Lindesmith L; Yount B; Moe CL; Baric RS
J Virol; 2002 Dec; 76(23):12335-43. PubMed ID: 12414974
[TBL] [Abstract][Full Text] [Related]
15. Induction of homologous and cross-reactive GII.4-specific blocking antibodies in children after GII.4 New Orleans norovirus infection.
Blazevic V; Malm M; Vesikari T
J Med Virol; 2015 Oct; 87(10):1656-61. PubMed ID: 25946711
[TBL] [Abstract][Full Text] [Related]
16. Identification of cross-reactive norovirus CD4+ T cell epitopes.
LoBue AD; Lindesmith LC; Baric RS
J Virol; 2010 Sep; 84(17):8530-8. PubMed ID: 20573810
[TBL] [Abstract][Full Text] [Related]
17. Norovirus GII.4 antibodies in breast milk and serum samples: their role preventing virus-like particles binding to their receptors.
Khodayar-Pardo P; Martínez-Costa C; Carmona-Vicente N; Buesa J
Pediatr Infect Dis J; 2014 Jun; 33(6):554-9. PubMed ID: 24830517
[TBL] [Abstract][Full Text] [Related]
18. Characterization of blockade antibody responses in GII.2.1976 Snow Mountain virus-infected subjects.
Swanstrom J; Lindesmith LC; Donaldson EF; Yount B; Baric RS
J Virol; 2014 Jan; 88(2):829-37. PubMed ID: 24173225
[TBL] [Abstract][Full Text] [Related]
19. Norovirus-specific mucosal antibodies correlate to systemic antibodies and block norovirus virus-like particles binding to histo-blood group antigens.
Tamminen K; Malm M; Vesikari T; Blazevic V
Clin Immunol; 2018 Dec; 197():110-117. PubMed ID: 30244152
[TBL] [Abstract][Full Text] [Related]
20. Serological Correlates of Protection against a GII.4 Norovirus.
Atmar RL; Bernstein DI; Lyon GM; Treanor JJ; Al-Ibrahim MS; Graham DY; Vinjé J; Jiang X; Gregoricus N; Frenck RW; Moe CL; Chen WH; Ferreira J; Barrett J; Opekun AR; Estes MK; Borkowski A; Baehner F; Goodwin R; Edmonds A; Mendelman PM
Clin Vaccine Immunol; 2015 Aug; 22(8):923-9. PubMed ID: 26041041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
